CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

Prospective Study on Asthma Control

Completed

Conditions: Asthma

First Posted Date: 2010-04-26

Last Posted Date: 2011-02-01

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 2875

Registration Number: NCT01110460

Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)

Completed

Conditions: Respiratory Distress Syndrome, Newborn

First Posted Date: 2010-04-13

Last Posted Date: 2012-04-06

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 972

Registration Number: NCT01102543

Locations: 🇫🇷
Laboratoire Chiesi S.A., Courbevoie, France

Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: CHF 5188 pMDI
Drug: Budesonide extrafine pMDI
Drug: Seretide(r) Evohaler(r)

First Posted Date: 2010-02-18

Last Posted Date: 2017-03-30

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 113

Registration Number: NCT01070524

Locations: 🇬🇧
The Medicines Evaluation Unit Ltd, The Langley Building, Southmoor Road, Manchester, United Kingdom

Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Formoterol

First Posted Date: 2009-09-04

Last Posted Date: 2011-12-13

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 457

Registration Number: NCT00972140

Locations: 🇵🇱
Prof. Iwona Graelewska Rzymowska, Lodz, Lódz, Poland

Efficacy of Nebulized Beclomethasone Dipropionate (BDP) in the Treatment of Moderate Croup

Phase 3

Terminated

Conditions: Croup

Interventions: Drug: beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml
Drug: Placebo solution for nebulisation 2 ml

First Posted Date: 2009-07-13

Last Posted Date: 2011-04-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 6

Registration Number: NCT00938353

Locations: 🇮🇹
Ospedale San Giuseppe Moscati, Avellino, Italy

BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: CHF1535
Drug: Formoterol fumarate

First Posted Date: 2009-06-30

Last Posted Date: 2021-10-29

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 1199

Registration Number: NCT00929851

Locations: 🇬🇧
UCL Medical School, London, United Kingdom

FACTO Study (Foster® As Complete Treatment Option)

Phase 4

Completed

Conditions: Asthmatic Patients

Interventions: Drug: FOSTER
Drug: Seretide

First Posted Date: 2009-05-13

Last Posted Date: 2017-03-30

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 431

Registration Number: NCT00901368

Locations: 🇫🇷
Hôpital Nord, Marseille, France
🇳🇱
Atrium Medisch Centrum Heerlen,, Heerlen, Netherlands
🇩🇪
Allergologie imUmkreis der Praxis Pneumologie, Gelsenkirchen, Nordrhein-Westfalen, Germany

and more 1 locations

A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®

Phase 3

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: tobramycin / Bramitob
Drug: tobramycin / TOBI

First Posted Date: 2009-04-21

Last Posted Date: 2018-06-27

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 324

Registration Number: NCT00885365

Locations: 🇫🇷
Hopital Arnaud de Villeneuve, Clinique des maladies respiratoires, Montpellier, France
🇨🇿
Centrum pro cystickou fibrosu, Pediatricka klinika UK 2.LF, Fakultní nemocnice v Motole, Praha, Czechia
🇫🇷
CHR Clemenceau, Caen, France

and more 40 locations

Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Foster BDP/Formoterol
Drug: CHF 1535 Next DPI
Drug: Placebo

First Posted Date: 2009-03-24

Last Posted Date: 2017-03-30

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 69

Registration Number: NCT00868023

Locations: 🇬🇧
Pr DS SINGH, Manchester, United Kingdom

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI

First Posted Date: 2009-03-16

Last Posted Date: 2017-03-30

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 286

Registration Number: NCT00862264

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy